1-3 of 3
Elyce Turba
Close
Sort by
Journal Articles

Sequential Therapy with Ofatumumab, High Dose Methylprednisolone and Lenalidomide Is a Safe and Effective Regimen for the Treatment of Previously Treated and Untreated CLL/SLL: The Hilo Trial

Javier Pinilla-Ibarz, Julio C Chavez, MD, Elyce Turba, RN, MSN, OCN, Lisa Nodzon, PhDANP, Jennifer rock-Klotz, BA, Samir Dalia, MD, Rami S. Komrokji, MD, Frederick L. Locke, MD, Mohamed A Kharfan-Dabaja, MD, Celeste M. Bello, MD
Journal: Blood
Blood (2015) 126 (23): 2941.
https://doi.org/10.1182/blood.V126.23.2941.2941
Published: 2015
Journal Articles

Sézary Syndrome: Clinicopathological and Immunophenotypical Characteristics and Outcomes

Christa Roe, RN, BS, OCN, Jennifer Rock-Klotz, BA, Elyce Turba, RN, MSN, OCN, Christopher Rodriguez Salamanca, PA, Janice Bennett, MS, ARNP-C, Farrah Farquharson, PA, Sem Bastien, MS, ARNP-C, Barbara Williams, RN, BS, OCN, Rebecca Levy, MS, ARNP-C, Yibo Li, BS, Michael Montejo, MD, Ernesto Ayala, MD, Pedro Horna, MD, Lewis F Glass, MD, Rami S. Komrokji, MD, Lubomir Sokol, MD PhD
Journal: Blood
Blood (2015) 126 (23): 1546.
https://doi.org/10.1182/blood.V126.23.1546.1546
Published: 2015
Journal Articles

Results of a phase 2 study of pacritinib (SB1518), a JAK2/JAK2(V617F) inhibitor, in patients with myelofibrosis

Clinical Trials & Observations
Rami S. Komrokji, John F. Seymour, Andrew W. Roberts, Martha Wadleigh, L. Bik To, Robyn Scherber, Elyce Turba, Andrew Dorr, Joy Zhu, Lixia Wang, Tanya Granston, Mary S. Campbell, Ruben A. Mesa
Journal: Blood
Blood (2015) 125 (17): 2649–2655.
https://doi.org/10.1182/blood-2013-02-484832
Published: 2015
Includes: Supplemental data